扶正抗瘤胶囊联合GP方案对晚期非小细胞肺癌血清VEGF表达和疗效的影响(1)
【摘要】 目的：观察扶正抗瘤胶囊联合GP方案对晚期非小细胞肺癌(NSCLC)血清VEGF表达和临床疗效的影响。方法：选取2014年1月-2015年6月本院收治的晚期NSCLC患者112例作为研究对象，使用随机数字表法将其分为对照组54例和治疗组58例，对照组使用GP方案进行化疗，治疗组在对照组基础上使用扶正抗瘤胶囊6 g，3 次/d，第1～40天口服。观察两组患者治疗前后血管内皮生长因子(VEGF)水平、临床疗效、不良反应及生活质量情况。结果：两组治疗前VEGF水平比较差异无统计学意义(P>0.05)，治疗后均较治疗前降低，且治疗组降低更为明显，比较差异均有统计学意义(P<0.05)；治疗组临床总有效率为87.93%，高于对照组的59.26%，治疗组各项不良反应发生情况均低于对照组，生活质量改善情况均优于对照组，比较差异均有统计学意义(P<0.05)。结论：扶正抗瘤胶囊联合GP方案对晚期NSCLC具有良好的治疗作用，能够降低血清VEGF的表达，提高临床疗效，减轻副作用。
【关键词】 扶正抗瘤胶囊； GP方案； 晚期非小细胞肺癌； 血清VEGF表达
【Abstract】 Objective：To observe the effects of Fuzheng anti-tumor capsule combined with GP regimen for advanced non-small cell lung cancer serum VEGF expression in small cell lung cancer.Method：From January 2014 to June 2015，112 cases of advanced NSCLC in our hospital were selected as the research objects，they were divided into the 54 cases of the control group and 58 cases of the treatment group according to the random number table method.The control group was treated with GP chemotherapy，the treatment group was treated with Fuzheng anti-tumor capsule 6 g，3 times a day，1 to 40 days of oral based on the control group.The changes of vascular endothelial growth factor(VEGF)，clinical efficacy，adverse reaction and quality of life of two groups were observed.Result：There was no significant difference in VEGF level of two groups before treatment(P>0.05)，after treatment was lower than before treatment and the treatment group decreased more significantly，the differences were statistically significant(P<0.05).The total effective rate of treatment group was 87.93%，higher than 59.26% of the control group，the incidence of adverse reactions in the treatment group were lower than that in the control group，the quality of life improvement situation was better than that of the control group，the differences were statistically significant(P<0.05).Conclusion：Fuzheng anti-tumor capsule combined with GP regimen for advanced non-small cell lung cancer has good curative effect，it can reduce the expression of serum VEGF，improve clinical efficacy and reduce the side effects.
【Key words】 Fuzheng anti-tumor capsule； GP regimen； Advanced non-small cell lung cancer； Serum VEGF expression
肺癌是临床上最常见的恶性肿瘤之一，我国其发病率居恶性肿瘤发病率的首位，且今年来仍然出现上升趋势，对人类的健康和生命发生严重的危害[1]。肺癌根据组织学分类可分为小细胞肺癌和非小细胞肺癌(NSCLC)，后者的发病率为70%～80%，在肺癌中占较大比重[2]。早、中期肺癌可以手术治疗，但是晚期肺癌通常以化疗为主要手段。化疗的副作用较大，对身体损害严重，为了解决这一问题，本院今年以来使用扶正抗癌胶囊联合药物化疗对NSCLC患者进行治疗，取得了良好疗效，现报道如下。
1 资料与方法
1.1 一般资料 随机选取2014年1月-2015年6月于本院肿瘤科住院的晚期NSCLC患者112例，所有患者均经过组织病理学确诊，根据《重要新药临床研究指导原则》2002年版相关标准确定为气阴两虚证。其中男70例，女42例；年龄45～75岁，平均(56.44±7.38)岁；病理分型：鳞癌患者35例，腺癌患者51例，混合癌患者26例。使用随机数字表将其分为治疗组58例和对照组, 百拇医药(呙清临 张在翔 肖康 罗显林)
【关键词】 扶正抗瘤胶囊； GP方案； 晚期非小细胞肺癌； 血清VEGF表达
【Abstract】 Objective：To observe the effects of Fuzheng anti-tumor capsule combined with GP regimen for advanced non-small cell lung cancer serum VEGF expression in small cell lung cancer.Method：From January 2014 to June 2015，112 cases of advanced NSCLC in our hospital were selected as the research objects，they were divided into the 54 cases of the control group and 58 cases of the treatment group according to the random number table method.The control group was treated with GP chemotherapy，the treatment group was treated with Fuzheng anti-tumor capsule 6 g，3 times a day，1 to 40 days of oral based on the control group.The changes of vascular endothelial growth factor(VEGF)，clinical efficacy，adverse reaction and quality of life of two groups were observed.Result：There was no significant difference in VEGF level of two groups before treatment(P>0.05)，after treatment was lower than before treatment and the treatment group decreased more significantly，the differences were statistically significant(P<0.05).The total effective rate of treatment group was 87.93%，higher than 59.26% of the control group，the incidence of adverse reactions in the treatment group were lower than that in the control group，the quality of life improvement situation was better than that of the control group，the differences were statistically significant(P<0.05).Conclusion：Fuzheng anti-tumor capsule combined with GP regimen for advanced non-small cell lung cancer has good curative effect，it can reduce the expression of serum VEGF，improve clinical efficacy and reduce the side effects.
【Key words】 Fuzheng anti-tumor capsule； GP regimen； Advanced non-small cell lung cancer； Serum VEGF expression
肺癌是临床上最常见的恶性肿瘤之一，我国其发病率居恶性肿瘤发病率的首位，且今年来仍然出现上升趋势，对人类的健康和生命发生严重的危害[1]。肺癌根据组织学分类可分为小细胞肺癌和非小细胞肺癌(NSCLC)，后者的发病率为70%～80%，在肺癌中占较大比重[2]。早、中期肺癌可以手术治疗，但是晚期肺癌通常以化疗为主要手段。化疗的副作用较大，对身体损害严重，为了解决这一问题，本院今年以来使用扶正抗癌胶囊联合药物化疗对NSCLC患者进行治疗，取得了良好疗效，现报道如下。
1 资料与方法
1.1 一般资料 随机选取2014年1月-2015年6月于本院肿瘤科住院的晚期NSCLC患者112例，所有患者均经过组织病理学确诊，根据《重要新药临床研究指导原则》2002年版相关标准确定为气阴两虚证。其中男70例，女42例；年龄45～75岁，平均(56.44±7.38)岁；病理分型：鳞癌患者35例，腺癌患者51例，混合癌患者26例。使用随机数字表将其分为治疗组58例和对照组, 百拇医药(呙清临 张在翔 肖康 罗显林)